497 related articles for article (PubMed ID: 32666341)
1. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
Iribe Y; Furuya M; Shibata Y; Yasui M; Funahashi M; Ota J; Iwashita H; Nagashima Y; Hasumi H; Hayashi N; Makiyama K; Kondo K; Tanaka R; Yao M; Nakaigawa N
Fam Cancer; 2021 Jan; 20(1):75-80. PubMed ID: 32666341
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
[TBL] [Abstract][Full Text] [Related]
3. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.
Choi Y; Keam B; Kim M; Yoon S; Kim D; Choi JG; Seo JY; Park I; Lee JL
Cancer Res Treat; 2019 Oct; 51(4):1549-1556. PubMed ID: 30913859
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas.
Furuya M; Iribe Y; Nagashima Y; Kambe N; Ohe C; Kinoshita H; Sato C; Kishida T; Okubo Y; Numakura K; Nanjo H; Nakaigawa N; Makiyama K; Hasumi H; Iwashita H; Ohta J; Kitamura H; Nakajima T; Yoshida T; Nakagawa M; Tanaka R; Yao M
J Clin Pathol; 2020 Dec; 73(12):819-825. PubMed ID: 32376712
[TBL] [Abstract][Full Text] [Related]
6. Prospective Detection of Germline Mutation of Fumarate Hydratase in Women With Uterine Smooth Muscle Tumors Using Pathology-based Screening to Trigger Genetic Counseling for Hereditary Leiomyomatosis Renal Cell Carcinoma Syndrome: A 5-Year Single Institutional Experience.
Rabban JT; Chan E; Mak J; Zaloudek C; Garg K
Am J Surg Pathol; 2019 May; 43(5):639-655. PubMed ID: 30741757
[TBL] [Abstract][Full Text] [Related]
7. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
[TBL] [Abstract][Full Text] [Related]
8. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
9. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
10. Hereditary leiomyomatosis and renal cell carcinoma syndrome associated uterine smooth muscle tumors: Bridging morphology and clinical screening.
Garg K; Rabban J
Genes Chromosomes Cancer; 2021 Mar; 60(3):210-216. PubMed ID: 33099845
[TBL] [Abstract][Full Text] [Related]
11. Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC): Report of a Family Pedigree.
Choi G; Kimonis V; Hall K; Lau WL
Am J Med Sci; 2020 Dec; 360(6):724-727. PubMed ID: 32703534
[TBL] [Abstract][Full Text] [Related]
12. Advanced fumarate hydratase-deficient renal cell carcinoma responding to combination immune checkpoint inhibitors.
Howells E; Wigston L; Mackie G; Tran B; Nott L
Can J Urol; 2023 Jun; 30(3):11558-11561. PubMed ID: 37344468
[TBL] [Abstract][Full Text] [Related]
13. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
[TBL] [Abstract][Full Text] [Related]
14. Germline Whole-Gene Deletion of FH Diagnosed from Tumor Profiling.
Ueki A; Sugano K; Misu K; Aimono E; Nakamura K; Tanishima S; Tanaka N; Mikami S; Hirasawa A; Ando M; Yoshida T; Oya M; Nishihara H; Kosaki K
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360727
[TBL] [Abstract][Full Text] [Related]
15. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
Ooi A
Semin Cancer Biol; 2020 Apr; 61():158-166. PubMed ID: 31689495
[TBL] [Abstract][Full Text] [Related]
16. Complete Response of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-Associated Renal Cell Carcinoma to Pembrolizumab Immunotherapy: A Case Report.
Wang T; Huang Y; Huang X; Lv Z; Tian S; Ma X; Zhang X
Front Oncol; 2021; 11():735077. PubMed ID: 34722283
[TBL] [Abstract][Full Text] [Related]
17. Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-Associated Renal Cell Carcinoma Showing High FDG Uptake.
Xiao Z; Dong A; Wang Y
Clin Nucl Med; 2019 May; 44(5):420-423. PubMed ID: 30762823
[TBL] [Abstract][Full Text] [Related]
18. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab.
Sekito T; Takamoto A; Kobayashi Y; Mitsui M; Watari S; Kubota R; Sadahira T; Iwata T; Nishimura S; Edamura K; Sako T; Araki M; Watanabe M; Watanabe T; Shibata R; Ennishi D; Nasu Y
Acta Med Okayama; 2021 Jun; 75(3):397-402. PubMed ID: 34176946
[TBL] [Abstract][Full Text] [Related]
19. A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC).
Bhola PT; Gilpin C; Smith A; Graham GE
Fam Cancer; 2018 Oct; 17(4):615-620. PubMed ID: 29423582
[TBL] [Abstract][Full Text] [Related]
20. Review of hereditary leiomyomatosis renal cell carcinoma with focus on clinical and pathobiological aspects of renal tumors.
Kuroda N; Ohe C; Kato I; Furuya M; Baba M; Nagashima Y; Nakatani Y; Murakami I; Zhou M; Michal M; He O; Amin MB
Pol J Pathol; 2017; 68(4):284-290. PubMed ID: 29517197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
